GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (STU:CF5) » Definitions » Fixed Maturity Investment

Can Fite Biofarma (STU:CF5) Fixed Maturity Investment


View and export this data going back to 2019. Start your Free Trial

What is Can Fite Biofarma Fixed Maturity Investment?

Fixed Maturity Investment only applies to insurance companies.


Can Fite Biofarma (STU:CF5) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).